PMGC Holdings (ELAB)
NASDAQ:ELAB
Want to see ELAB full AI Analyst Report?
Top Page
PMGC Holdings
(NASDAQ:ELAB)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.50
â–¼(-3.23% Downside)
Action:Reiterated
Date:05/23/26
The score is held down mainly by weak financial quality (large losses and persistent cash burn) and bearish technical signals (price below major moving averages with negative MACD). Corporate events are somewhat constructive but are tempered by dilution/financing risk, while valuation signals are inconclusive due to negative earnings and no dividend.
Positive Factors
Long-term aerospace & defense supply contracts
Multi-year supply agreements and documented performance commitments create durable revenue visibility, raise switching costs, and support margin stability. For a precision manufacturing roll-up, recurring defense contracts reduce volatility and underpin steady cash generation as certification and delivery histories accumulate.
Negative Factors
Persistent negative operating and free cash flow
Sustained free‑cash‑flow burn forces ongoing reliance on external financing and limits capacity to invest organically or fund integration costs. Over months this heightens liquidity risk, increases financing costs, and makes the firm vulnerable to disruptions if equity facilities or reserved capital become constrained.
Read all positive and negative factors
Positive Factors
Negative Factors
Long-term aerospace & defense supply contracts
Multi-year supply agreements and documented performance commitments create durable revenue visibility, raise switching costs, and support margin stability. For a precision manufacturing roll-up, recurring defense contracts reduce volatility and underpin steady cash generation as certification and delivery histories accumulate.
Read all positive factors
PMGC Holdings (ELAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.09M
Dividend YieldN/A
Average Volume (3M)89.87K
Price to Earnings (P/E)―
Beta (1Y)2.56
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,543,751
10 Day Avg. Volume35,159
30 Day Avg. Volume89,868
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.37
Price to Sales (P/S)4.90
P/FCF Ratio-0.45
Enterprise Value/Market Cap-0.41
Enterprise Value/Revenue-2.59
Enterprise Value/Gross Profit-20.40
Enterprise Value/Ebitda0.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PMGC Holdings Business Overview & Revenue Model
Company Description
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to ...
How the Company Makes Money
null...
PMGC Holdings Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.27M | 590.08K | 2.47M | 1.71M | 766.28K | 827.00 |
| Gross Profit | 161.28K | 74.81K | 1.80M | 1.13M | 447.31K | -2.02K |
| EBITDA | -9.03M | -7.27M | -3.20M | -3.66M | -1.79M | -782.30K |
| Net Income | -11.11M | -7.71M | -6.25M | -4.30M | -1.80M | -784.74K |
Balance Sheet | ||||||
| Total Assets | 26.03M | 12.87M | 8.99M | 5.19M | 1.89M | 666.25K |
| Cash, Cash Equivalents and Short-Term Investments | 15.09M | 5.40M | 3.98M | 3.33M | 1.15M | 411.86K |
| Total Debt | 7.96M | 2.64M | 0.00 | 210.49K | 283.22K | 0.00 |
| Total Liabilities | 13.43M | 5.03M | 2.33M | 1.36M | 760.87K | 215.62K |
| Stockholders Equity | 12.61M | 7.84M | 6.66M | 3.83M | 1.13M | 450.63K |
Cash Flow | ||||||
| Free Cash Flow | -7.93M | -6.38M | -5.49M | -4.57M | -1.62M | -693.42K |
| Operating Cash Flow | -7.57M | -5.93M | -5.49M | -4.56M | -1.59M | -660.93K |
| Investing Cash Flow | -5.03M | -2.77M | -610.56K | -11.19K | -32.03K | -32.48K |
| Financing Cash Flow | 21.59M | 10.12M | 6.76M | 6.74M | 2.36M | 1.09M |
PMGC Holdings Technical Analysis
Negative
1.55
Price Trends
3.33
Negative
9.72
Negative
69.33
Negative
Market Momentum
-0.58
Negative
38.16
Neutral
11.98
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELAB, the sentiment is Negative. The current price of 1.55 is below the 20-day moving average (MA) of 2.10, below the 50-day MA of 3.33, and below the 200-day MA of 69.33, indicating a bearish trend. The MACD of -0.58 indicates Negative momentum. The RSI at 38.16 is Neutral, neither overbought nor oversold. The STOCH value of 11.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELAB.
PMGC Holdings Risk Analysis
PMGC Holdings disclosed 79 risk factors in its most recent earnings report. PMGC Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PMGC Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $5.70M | -0.22 | -82.17% | ― | -34.06% | 79.61% | |
49 Neutral | $7.92M | -0.08 | -197.11% | ― | ― | 99.30% | |
48 Neutral | $1.48M | -0.04 | -63.03% | ― | ― | 88.07% | |
45 Neutral | $8.09M | >-0.01 | -82.41% | ― | ― | ― | |
42 Neutral | $138.16M | -0.39 | -1028.81% | ― | ― | 61.43% |
* Healthcare Sector Average
ELAB
PMGC Holdings
1.78
-195.62
-99.10%
BDRX
Biodexa Pharmaceuticals
3.28
-54.22
-94.30%
INDP
Indaptus Therapeutics
1.22
-7.86
-86.56%
INM
InMed Pharmaceuticals
1.72
-1.04
-37.68%
CNSP
CNS Pharmaceuticals
5.42
-7.54
-58.18%
PMGC Holdings Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
PMGC Holdings Completes Acquisition of A&B Aerospace Business
Positive
May 13, 2026
On May 12, 2026, PMGC Holdings Inc. completed the acquisition of 100% of AB Aerospace, Inc. for $4.5 million in cash, subject to customary working capital and cash balance adjustments and a $225,000 indemnification holdback tied to pending litigat...
Business Operations and StrategyRegulatory Filings and Compliance
PMGC Subsidiary Expands Muscle Health Patent Portfolio
Positive
Apr 28, 2026
On April 28, 2026, NorthStrive Biosciences filed a new U.S. patent application for its myostatin‑engineered probiotic EL-22, expanding the technology into human pharmaceutical applications targeting muscle loss. The application covers formul...
Business Operations and StrategyProduct-Related Announcements
PMGC Subsidiary Secures Exclusive Option for GPS-Denied Drone Navigation
Positive
Apr 23, 2026
On April 23, 2026, NorthStrive Defense Tech LLC announced it had secured an exclusive license option over a U.S.-patented cooperative navigation system designed for drones and unmanned aircraft systems operating in GPS-jammed, spoofed, or denied e...
Business Operations and StrategyRegulatory Filings and Compliance
PMGC Subsidiary SVM Secures Long-Term Aerospace Supply Deal
Positive
Apr 21, 2026
On April 21, 2026, SVM Machining, Inc., a wholly owned subsidiary of PMGC Holdings, signed a long-term agreement to supply mission-critical aerospace and defense components to California-based Turbo-Jet Products Co., Inc. The contract, SVM’s...
Business Operations and StrategyPrivate Placements and Financing
PMGC Holdings Secures $40 Million Equity Purchase Facility
Positive
Apr 17, 2026
On April 16, 2026, PMGC Holdings Inc. entered into a securities purchase agreement with an institutional investor establishing a $40 million equity purchase facility structured as pre-paid share purchases. An initial tranche of about $10 million, ...
Business Operations and Strategy
PMGC Holdings Expands Aerospace Defense Supply Agreements Portfolio
Positive
Apr 9, 2026
On April 9, 2026, AGA Precision Systems LLC, a precision CNC aerospace and defense manufacturer owned by PMGC Holdings Inc., signed a second long-term supply agreement with a globally recognized Tier 1 aerospace and defense company, after a prior ...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
PMGC Utilizes Equity Facility to Fund Acquisition Strategy
Positive
Apr 8, 2026
On April 8, 2026, PMGC Holdings said it had fully utilized the $20 million commitment under its equity purchase facility with Streeterville Capital, reinforcing its cash position to fund a near-term acquisition pipeline and integration efforts. Ma...
Business Operations and StrategyProduct-Related Announcements
PMGC Explores Advanced Dual-Domain Drone Logistics Technology
Positive
Apr 6, 2026
On April 6, 2026, NorthStrive Defense Tech LLC, a wholly owned subsidiary of PMGC Holdings Inc., announced it had secured an exclusive option to license U.S. Patent No. 12,291,334, a next‑generation drone system that transports cable‑s...
Business Operations and Strategy
PMGC Launches NorthStrive Subsidiary Targeting Defense Technology Growth
Positive
Apr 2, 2026
On April 2, 2026, PMGC Holdings Inc. launched NorthStrive Defense Tech LLC, a wholly owned subsidiary created to target the high-growth defense technology market, with a focus on drones, autonomous systems and next-generation unmanned defense solu...
Business Operations and Strategy
PMGC Holdings Updates Northstrive Licensing Milestones with MOA
Neutral
Mar 27, 2026
On March 24, 2026, Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., executed a third amendment to its license agreement with Korea’s MOA Life Plus Co., Ltd., originally signed on April 30, 2024. The amendment replaces the pr...
Business Operations and StrategyRegulatory Filings and Compliance
PMGC Holdings Subsidiary Gains ITAR Defense Compliance Status
Positive
Mar 24, 2026
On March 24, 2026, PMGC Holdings said its subsidiary SVM Machining, Inc. has completed registration under the International Traffic in Arms Regulations, confirming compliance with U.S. export-control rules for defense articles and services. The IT...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
PMGC Holdings Updates Executive Consulting Fee Agreements
Neutral
Mar 23, 2026
On March 17, 2026, PMGC Holdings Inc. amended its consulting agreement with GB Capital Ltd., the entity wholly owned by CEO, CFO, and director Graydon Bensler, setting GB Capital’s annual consulting fee at $300,000 and confirming that this l...
Business Operations and StrategyStock Split
PMGC Holdings Announces 1-for-6 Reverse Stock Split
Neutral
Mar 10, 2026
PMGC Holdings Inc. said on March 4, 2026, that it will implement a 1-for-6 reverse stock split of its common stock, effective March 10, 2026, consolidating every six issued, outstanding and authorized shares into one share and assigning a new CUSI...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
PMGC Holdings Enters Fourth Secured Pre-Paid Equity Deal
Negative
Mar 3, 2026
On February 6, 2026, PMGC Holdings completed a fourth secured pre-paid equity purchase with an institutional investor, carrying an original principal of about $8.15 million and net proceeds of roughly $7.46 million, largely deposited into a contro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.